Background: Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) predict better outcome to EGFR tyrosine kinase inhibitors. The most common mutations are exon 19 deletions (most frequently E746 -A750) and L858R point mutation in exon 21. Here, we evaluated the accuracy of novel EGFR mutation-specific antibodies in a Japanese cohort with NSCLC and compared with direct DNA sequencing and clinical outcome. Materials and Methods: Immunohistochemistry (IHC) using antibodies specific for the E746 -A750 and L858R mutations in EGFR was performed on tissue microarrays of tumors from 70 gefitinib treated NSCLC patients. Extracted DNA was sequenced for mutational analysis of EGFR exons 18 to 21. Results: DNA sequencing showed EGFR mutations in 41 patients (58.6%) and exon 19 deletions in 18 patients (25.7%), 11 of 18 (61%) had a deletion in the range of E746 -A750 and 12 (17.1%) had exon 21 mutations (L858R). IHC showed, for the E746 -A750 and L858R mutations, sensitivity (81.8 and 75%), specificity (100 and 96.6%), positive predictive value (100 and 81.8%), and negative predictive value (96.7 and 94.9%). Analysis for objective response rates and survival were not correlated to IHC staining, although the combined staining showed nonsignificant trends toward better overall survival for patients with EGFR mutations.
pidermal growth factor receptor (EGFR) mutation status has a critical role in the treatment algorithm of advanced non-small cell lung cancer (NSCLC) in first-, second-, and third-line therapy. EGFR tyrosine kinase inhibitors (TKIs) have recently been shown to be superior to chemotherapy in EGFR-mutated NSCLC patients, [1] [2] [3] [4] and gefitinib is approved in Europe for patients harboring EGFR mutations. Therefore, evaluating the EGFR mutation status is believed to be highly important before any therapy decision is undertaken in advanced NSCLC.
Activating mutations in exons 18 to 21 of EGFR were initially identified in NSCLC patients with clinical response to gefitinib. 5, 6 These somatic mutations in the kinase domain of EGFR exist in approximately 10 to 16% of NSCLC specimens in the United States and Europe 3 and 30 to 50% in Asia 7 with 28 distinct mutations. 8, 9 The exon 19 deletions (including E746 -A750) account for ϳ45% of the total mutations. Eleven different mutations, resulting in deletion of three to seven amino acids, have been detected in exon 19 , and all are centered around the uniformly deleted codons for amino acids 747 to 749. The second major mutation group observed is the missense mutations found in exon 21 (39 -45%), followed by mutations in exon 20 and 18 (6 -10%) . Among the missense mutations in exon 21, the point mutation, L858R, accounts for 39% of the total mutations in exon 21 . Patients with EGFR mutations have a greater response rate to EGFR-TKIs (60 -80%) than patients with EGFR wild-type tumors or unknown mutation status (10 -20%). 10 Clinically, there seem to be differences in outcome based on the type of mutations. Patients with exon 19 deletions demonstrate a higher response rate and longer survival with EGFR-TKI therapy than patients with point mutations in exon 21. 10 -13 EGFR mutations tend to be associated with adenocarcinoma, East Asian ethnicity, and never smokers.
There are many methods to detect mutations (i.e., DxS EGFR Mutation Kit (Dxs Ltd., Manchester, UK), high-resolution melting analysis 14 -16 ). However, the most common is direct sequencing of the polymerase chain reaction (PCR)-amplified exon sequences. Although these methods provide information about numerous genetic mutations, they are not always available. Most recently, immunohistochemistry (IHC) mutation-specific antibodies have been developed for EGFR mutations in exons 19 and 21, and encouraging data have been presented. 17, 18 In this study, we tested the performance of IHC-based methodology to define EGFR mutation in a retrospective cohort of 70 Japanese patients and validated the data with DNA sequencing.
PATIENTS AND METHODS

Patients
The study included 70 patients treated with gefitinib as monotherapy (250 mg/day) for their recurrent diseases after they had undergone surgery between November 1997 and July 2007 at the Tokyo Medical University Hospital. Their clinical characteristics are detailed in Table 1 . All patients were Japanese, aged between 27 and 88 years (mean 59.9 years), 36 (51%) men, 41 (48%) smokers, and 29 (41%) never smokers. Progression-free survival (PFS) and overall survival were counted from the time of gefitinib therapy to progression or death accordingly. The median survival time was 15.3 months (range 0.1-77.5 months). The median time to progression was 7.5 months (range 0.1-43.3 months). All patients had histologically confirmed NSCLC (57 adenocarcinoma, 7 squamous cell carcinoma, 4 large cell carcinoma, and 2 other NSCLC) with measurable, locally advanced or metastatic disease, progressing or relapsing after the complete resection. On pathologic staging at surgery, 19 11 patients were staged as IA, 10 as IB, 8 as IIA, 3 as IIB, 28 as  IIIA, 7 as IIIB, and 3 as IV.
Assessment of tumor regression was conducted according to the RECIST criteria. 20 Tumor response for gefitinib therapy was assessed by computer tomography scan, with a confirmatory evaluation repeated in patients with complete response (CR), partial response (PR), stable disease (SD), and progressive disease at least 4 weeks after the initial determination of response. During treatment, assessments were performed every 4 weeks for the first 4 months and then every 8 weeks until disease progression. The RECIST 20 recommended that duration of SD should specify the minimal time interval required between two measurements for determination of SD. Therefore, disease control rate (DCR ϭ CR ϩ PR ϩ SD) was evaluated at 12 weeks. Of the studied patients, 6 (9%) received gefitinib as their first systemic anticancer therapy after relapse, 33 (47%) received gefitinib as secondline therapy, and 31 (44%) patients as more than or equal to third-line therapy. For objective response rate (ORR) calculation, we considered only patients who were treated by gefitinib for at least 4 weeks (N ϭ 62).
Tissue Microarrays
Tissue microarrays (TMAs) were constructed from the primary resected tumors according to the procedure described in the previous reports. 21, 22 Briefly, the most representative tumor areas were carefully selected and marked on the hematoxylin and eosin-stained slide to construct the microarrays, and the TMA were assembled using a tissue arraying instrument (J.M. and T.N., Department of Anatomic Pathology, Tokyo Medical University Hospital, Tokyo, Japan). Samples of the specimens were routinely obtained by collecting three replicate core samples of the tumor (core size of 1.2 mm) from different areas. Normal liver tissues were used for control and slide orientation purposes. TaqHS , 100 ng template DNA, and 0.5 l of each primer (SRL, Tachikawa-shi, Tokyo, Japan). PCR products were then sequenced with a 3100 Genetic Analyzer (Applied Biosystems, Chuou-ku, Tokyo, Japan).
EGFR Mutation-Specific IHC Staining
Serial 4-m-thick tissue sections were cut from the TMA for IHC-based EGFR exons 19 and 21 mutation analysis. Histologic classification was determined on hematoxylin and eosin-stained sections according to the World Health Organization criteria. 23 The slides were incubated at 55°C overnight, then deparaffinized in xylene and rehydrated through a graded series of ethanol concentrations. Slides were labeled with antibody and protocol-specific bar codes and loaded into a Benchmark XT (Ventana Medical Systems Inc, Tucson, AZ) automated stainer. The slides were treated with Standard Cell Conditioning 1 for 60 minutes (Ventana Medical Systems Inc). The primary antibodies, EGFR E746 -A750del (catalog number 2085), Cell Signaling Technologies (CST, Danvers, MA) and EGFR L858R (catalog number 3197, CST), were both diluted 1:100 with SignalStain antibody diluent (CST) and manually applied to the TMA slides. The slides were then incubated at 37°C for 1 hour. The Ultraview Universal DAB detection kit (Ventana Medical Systems Inc) was used with an extra washing step selected. The slides were counterstained with hematoxylin and bluing at 4 minutes each. The slides were washed with mild soapy water and then dehydrated in ethyl alcohol (Surgipath, Richmond, IL) and Xylene (Surgipath) before applying coverslips.
Scoring Methodology
IHC staining was scored according to the University of Colorado IHC H-score criteria, with assessment of staining intensity (0 -4) multiplied by the percentage of positive cells (0 -100%) for each intensity for a final IHC score of 0 to 400. Tumors with H score more than or equal to 20 (i.e., 5%) were interpreted as positive, and tumors with an H score less than 20 (5%) were interpreted as negative. IHC staining overview was performed by a pathologist (M.P.) and a trained reader (Y.K.) at the University of Colorado Cancer Center. The final score per patient was calculated by the two readers using the core with the maximum value for each patient.
Statistic Analysis
Standard descriptive statistics and Kaplan-Meier survival curves were used. Differences in survival were determined by the log-rank test. Proportions were compared by means of 2 analysis. The differences were considered to be statistically significant when the p value is less than 0.05. SPSS for Windows Version 12.0 (SPSS Inc., Chicago, IL) was also used to calculate the sensitivity, specificity, and survival data.
RESULTS
For 70 NSCLC patients, the median interval between surgery and gefitinib treatment for the recurrence disease was 14.2 months (range 3-82.9 months). The majority of patients (81.4%) had adenocarcinoma histology. DNA sequencing mutation analysis showed EGFR mutations in 41 patients (58.6%): 18 patients (25.7%) had an exon 19 deletion, 18 patients (25.7%) had an exon 20 mutation, 12 patients (17.1%) had an exon 21 mutation (6 had 2573 TϾK and 6 had 2573 TϾG), and one patient (1.4%) had an exon 18 mutation (Table 1) . Among the 18 patients with exon 19 deletion, 7 had a deletion other than E746 -A750 (Table 2) . Overlapping mutations existed between exon 19 and exon 20 (four cases), exon 20 and exon 21 (three cases), and exon 18 and exon 20 (one case).
EGFR Mutation-Specific Antibody IHC Staining
Expression of EGFR, both E746 -A750 deleted and L858R point mutated, was evaluated in all 70 patients by IHC. The mutation-specific antibodies have distinct immunoreactivity for the plasma membrane of the tumor cells, with some weak cytoplasmic staining, as presented in Figure 1 . Table 2 summarizes all the cases with either positive direct sequencing or positive IHC staining. In addition, as tumors tend to be heterogeneous in their mutational status, Table 3 explores staining intensity over the examined core.
Exon 19 Deletion
IHC staining with the EGFR exon 19 E746 -A750 deletion specific antibody was seen in 9 of 11 patients (Tables 2-4) . Because the exon 19-specific antibody was designed specifically for the E746 -A750 deletion, we considered only those 11 patients who had DNA sequence verified deletions, 2236 to 2250 or 2235 to 2249, that resulted in E746 -A750 amino acid deletions as sequence positive. We observed a discrepancy relative to DNA sequencing in two cases (Cases 4 and 27; Table 2-4). Case 27 had IHC score of 5, but was scored as negative because of limited staining and the predetermined cutoff of 20. Case 4 was completely negative by IHC. The sensitivity, specificity, positive predictive values (PPVs), and the negative predictive values (NPVs) to detect exon 19 E746 -A750 deletions were 81.8, 100, 100, and 96.7%, respectively (Table 5) . If also the other seven deletions beyond the predefined antibody target were considered, the sensitivity, specificity, PPV, and NPV were 50, 100, 100, and 85.2%, respectively ( Table 5 ). The heterogeneity of staining with the mutation-specific antibodies was evaluated. With regard to the E746 -A750-specific antibody, the areas of poorly differentiated cells were stained more strongly than well-differentiated areas.
Exon 21 L858R
Of the 12 EGFR L858R-mutated cases detected by DNA sequencing, 11 were seen by the EGFR L858R mutation-specific antibody (Tables 2-4 ). DNA sequencing of exon 21 showed that nucleotide 2573 was mutated from T to G in six patients, but in six other patients, it was equivocal if there was a mutation because both T and G were seen at this position, thus labeled K. However, all the 12 cases were considered as L858R mutation based on DNA sequencing because it was not possible to discriminate the 2573K cases. Thus, for exon 21-specific L858R mutation, 9 of 12 patients with EGFR L858R mutation were stained positive by IHC. However, two other cases showed positive staining discordant with the DNA sequencing (cases 58 and 65, Tables 2-4), and three cases that showed no IHC staining were discordant with DNA sequencing (cases 5, 33, and 62). Therefore, the sensitivity, specificity, PPV, and NPV of the L858R antibody are 75, 96.6, 81.8, and 94.9%, respectively (Table 5) . However, the two cases of the discordant negative cases (cases 5 and 33, Tables 2 and 3 ) had a direct sequencing of 2573 TϾK. Therefore, based on the negative IHC staining, if one retrospectively classified those patients as negative for EGFR mutation, the sensitivity, specificity, PPV, and NPV of the L858R antibody are 90, 96.7, 81.8, and 98.3%, respectively. The heterogeneity of staining with the L858R-specific antibody, poorly differentiated areas, such as the solid central area, was stronger than well-differentiated areas, such as those showing lepidic growth.
Focusing on the clinical need to detect any common EGFR mutations, we calculated the yield of double staining (E746 -A750 and L858R) and found a 78.3% sensitivity and 95.7% specificity for detecting the predefined EGFR mutations and 43.9 and 99.9% to detect any exon19 deletion and L858R mutation (Table 5) .
Clinical Outcome
Sixty-two patients were treated by gefitinib for at least 4 weeks and were considered for outcome analysis (DCR) at To evaluate the contribution of the technology chosen, direct sequencing or mutation-specific IHC, for making clinical decisions, we calculated the clinical outcome for each of the methodologies relative to each of the relevant mutations (Table 6 ). When guided by DNA sequencing, any of the mutations (all exon 19 deletions, E746 -A750 deletions, and L858R mutations) had significantly better ORR and DCR compared with wild-type cases (Table 6 ). Conversely, if the decision would have been made by the mutation-specific IHC technique alone, no significant differences between the positive and negative cases would be found. The same holds true when considering the combination of the two antibodies. This is because of high ORR among cases with negative staining, which is most likely related to other types of EGFR mutations such as in exon 18, exon 20, or exon 19 but outside the E746 -A750 range. Importantly enough, in this cohort, patients harboring EGFR mutations in exon 20 showed a favorable outcome similar to patients harboring exon 19 mutation or L858R (Table 6 ).
DISCUSSION
In this study, we evaluated by IHC the sensitivity, the specificity, and the association to clinical outcome of novel mutation-specific antibodies for exon 19 (E746 -A750) and exon 21 (L858R) and compared it with DNA sequencing in a Japanese cohort with advanced NSCLC. The two EGFR mutations represent the majority of EGFR mutations in NSCLC. 24 The study demonstrated a high specificity (Ͼ96%) and sensitivity (Ͼ75% ; Table 5 ) to the predetermined mutations, which are targeted by these antibodies.
Recently, Yamamoto et al. 25 reported 569 mutations in 2880 lung cancer patients, and the distribution of EGFR mutations was as follows: 48.2% of exon 19, 42.7% of exon 21, 3.7% of exon 20, and 3.2% of exon 18. Together, exon 19 deletion and exon 21 mutations accounted for approximately 90% of all EGFR mutations in NSCLC. In our cohort, 27% of the patients had other mutations than these two mutation types, mainly (26%) exon 20 mutation. However, although we know that the E746 -A750 and L858R EGFR mutations in exons 19 and 21 are activating mutations sensitive to EGFR TKIs, it is not known at this time whether the other-noncanonical-mutations are sensitive to EGFR TKIs. In this study, however, we showed that patients harboring EGFR mutations in exon 20 also had a favorable outcome similar to patients harboring exon 19 mutation or L858R (Table 6 ).
The mutation-specific antibodies we used in this IHC study were designed to detect specific mutations, that is, E746 -A750 deletions and L858R point mutations. Indeed, the sensitivity and the specificity of IHC to detect E746 -A750 deletion were 81.8 and 100%, and 75 and 96.6% for L858R, respectively (or 90 and 96.7% for L858R if considering the two discussed cases as true negative). However, the IHC detection of exon 19 mutation covered only 61% of all the exon 19 cases in our cohort. If screening was performed by IHC for both L858R and E746 -A750 in our cohort, 18 of 70 (26%) of the patients would have been diagnosed as having EGFR mutation, which represents only 44% of the current EGFR-mutated cases. Therefore, for clinical decisions, because any existence of EGFR mutation might be important, negative IHC will require a validation by other technique before a clinical decision can be made. Previous studies that used these antibodies 17, 18 came to similar conclusions. Yu et al. 17 reported overall sensitivity to detect any EGFR mutation in 340 tumors of 92% and specificity of 99%, however, the rate of other EGFR mutations was relatively low in their cohort. Brevet et al. 18 just recently reported sensitivity of 85% to detect exon 19 deletion and of 95% to detect L858R point mutations in exon 21. Our data support these studies and are the first to associate this method with the clinical outcome, where positive antibody-specific IHC staining, for either of the antibodies, was associated with a nonsignificant trend toward a favorable outcome with positive staining (Figure 2 ).
IHC is a well-established method routinely applied in lung cancer diagnosis in clinical laboratories. IHC also leads for the simultaneous analysis of expression level of other proteins or protein modifications. IHC also allows for the analysis of small tissue samples or cytologic samples (body fluids, bronchial washings, and fine needle aspirates samples) and circulating tumor cells. 26 Thus, the detection of E746 -A750 and L858R EGFR protein-specific mutations by IHC would be a valuable addition to the current protocols used in the diagnosis and treatment of lung cancer and particularly useful for mass screening of NSCLC patients for EGFR mutations.
Recently, many studies have reported simple and highly sensitive nonsequencing methods for detecting EGFR mutations in small tumor tissue samples 26 -29 in addition to cytologic specimens (pleural effusion, aspiration cytologic specimens). 30 -34 These methods are reported to be quick and convenient. However, these methods have limitations, for example, many, if not all, biopsy specimens will also contain noncancerous lesions (e.g., scar lesion, inflammation, peripheral pre cancerous lesions). The aforementioned methods cannot distinguish between the cancerous and noncancerous materials unless the tumor cells are microdissected, whereas the IHC can be viewed by a pathologist, who discriminates the tissues and assess the cancer cells per se.
The discrepant results between IHC and DNA sequencing found in this study may result from differences in sample size of the TMA cores versus the large specimens used for DNA sequencing. In our study, we used TMAs, whereas in previous studies, 17, 18 specimens from the whole paraffinembedded blocks were used. Thus, a much smaller quantity of tumor specimen was used in our study. EGFR mutations may not be homogeneously dispersed throughout the tumor, so that even though a core contains tumor cells, it may randomly include only wild-type EGFR and miss mutation positive tumor cells compared with whole section assessment.
The limitation of our study pertaining to the clinical outcome analysis may be due to the heterogeneity of the studied clinical cohort, with regard to type of disease recurrence and line gefitinib treatment. Therefore, even though we have analyzed the outcome per line of therapy (data not shown), still, this is not an optimal cohort for analyzing the predictive performance of IHC to the clinical outcome. Likewise, we had a high rate of exon 20 (18/70; 26%) mutations, which decreased the power of the test to predict the clinical outcome, because patients harboring exon 20 EGFR mutation showed a better response to gefitinib in our cohort.
In summary, the accuracy of the used mutation-specific IHC for E746 -A750 and L858R is high for predefined EGFR mutations. We believe that IHC is suitable for screening NSCLC patients for existence of these predefined EGFR mutations, but negative results should be validated further before excluding them from EGFR-related therapy. Such IHC method might provide faster and wider test availability, requires less tumor material, allow histologic evaluation, and is more cost differential for a positive test.
